Our Current Portfolio at a Glance
Our EXIS™️ platform drives a portfolio of fully human antibody therapeutics across multiple disease areas. We are currently advancing candidates in Immunology & Inflammation, Obesity & Metabolic Disorders, and Oncology, with plans to expand into new indications.
Programs& Their Components
Hit Generation & ScreeningHit GenHits
AI OptimizationAIAI
Lead CharacterizationLead Char. Lead(Function & Developbility)
Biological ValidationBio Val. Bio
IND-Enabling StudiesINDIND
Phase 1Ph. 1P1
Immunology and Inflammation
TL1A/IL-23
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
TL1A/OX40
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
TL1A/A4B7
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
OX40/IL-31
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
IL-11
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
Obesity
GIPR*/
GLP-1
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
GIPR*/
GLP-1/
Glucagon
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
GIPR*/
GLP-1/
Activin
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
Activin
RIIA/B
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
GPR 75
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
Oncology
CD3
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
STEAP1
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
SLC7A11
C. HitsHits
AI
Lead
Cand.Bio
ClinicIND
P1
— Clinically-Validates
— Novel Targets
* — Antogonist